Could Amgen be the next stock to soar due to a GLP-1 drug?…
Could Amgen be the next stock to soar due to a GLP-1 drug?…
Eli Lillys (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction…
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make…
Eli Lilly just took a page out of Novo Nordisks book.…
…
Actress and healthcare advocate Halle Berry; geneticist Marlena Fejzo; and Daniel Skovronsky, chief scientific officer at pharmaceutical giant Eli Lilly,…
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting…
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watchs heart monitoring tech was…
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.…
…
…
Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.…
Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.…
…
…
Amgens update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and…
Novo Nordisk, Eli Lilly drop on Amgen competition concerns…
…
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.…
Heres what could happen next to Eli Lilly shares.…
Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli…
Novo Nordisk A/S is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in the US as it grapples…
…
…
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound…
LLY earnings call for the period ending March 31, 2024.…
The worlds most valuable drugmaker hiked its full-year sales and profit guidance, despite missing lighter-than-expected first-quarter revenue.…
These were some of the stocks making the largest moves in trading on Tuesday.…
These are some of the stocks posting the largest moves in premarket trading.…
Eli Lilly and Co (NYSE:LLY)’s weight loss medication Mounjaro drove impressive first-quarter earnings results for the US pharmaceuticals megacap. Mounjaro...…
INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly ist dank gut laufender Geschäfte mit Abnehmmitteln mit…
Eli Lilly, 3M, PayPal rise premarket; Coca-Cola, Tesla, McDonalds fall…
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in…
Eli Lilly stock climbs on gross margin beat, raised 2024 revenue outlook…
Eli Lilly lifts profit view on diabetes and weight-loss drug strength…
Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type…
…
Booming demand for weight loss and diabetes drugs like Ozempic, Wegovy, Mounjaro and Zepbound has vastly outpaced Novo Nordisk and…
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024…
The Food and Drug Administration said supplies of Zepbound and Mounjaro are expected to be limited through the second quarter,…
Theres no stopping this high-flying biotech.…
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.…
GREIFSWALD (dpa-AFX) - Die Greifswalder Pharmafirma Cheplapharm ist weiter auf Wachstumskurs. Im Geschäftsjahr 2023 sei ein…
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk…
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and…
…
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.…
…